Adjuvant immunotherapy in malignant melanoma: Impact of antibody formation against interferon-α on immunoparameters in vivo

Journal of Immunotherapy

Volumn 20, Issue 3, 1997, Pages 208-209

  Davis Daneshfar, A ^a   Bni, R ^a   von Wussow, P ^b   Joller, H ^c   Dummer, R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adjuvant treatment; Interferon antibodies; Interferon ; Malignant melanoma; Neopterin; Soluble interleukin 2 receptor; 2 microglobulin

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; CARDIOLIPIN ANTIBODY; INTERFERON ANTIBODY; INTERLEUKIN 2 RECEPTOR; NEOPTERIN; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; THYROGLOBULIN ANTIBODY;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIBODIES; ANTIBODY FORMATION; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; RECOMBINANT PROTEINS; SKIN NEOPLASMS;

EID: 0345019947     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199705000-00006     Document Type: Article

References (22)

1. Balkwill FR. Interferons. Lancet 1989;8646:1060-3.
2. Vallbracht A, Treuner J, Flehmig B, Joester KE, Niethammer D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 1981;289:496-7.
3. Trown PW, Kramer MJ, Dennin RJ, et al. Antibodies to human leucocyte interferons in cancer patients. Lancet 1983;1:81-94.
4. Figlin RA, Itri LM. Anti-interferon antibodies: a perspective. Semin Hematol 1988;25:9-15.
5. Caruso A, Bonfanti C, Colombrita D, et al. Natural antibodies to IFN-gamma in man and their increase during viral infection. J Immunol 1990;144:685-90.
6. von Wussow P, Jakschies D, Hartung K, Deicher H. Presence of interferon and anti-interferon in patients with systemic lupus ery-thematosus. Rheumatol Int 1988;8:225-30.
7. Panem S, Check IJ, Henriksen D, Vilcek J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J Immunol 1982;129:1-3.
8. Ambrus JL, Ambrus JJ, Chadha KC. Interferon inhibition in lupus erythematosus [Letter], N Engl J Med 1988;319:582-3.
9. Dummer R, Hauschild A, Becker J. Adjuvant treatment of high-risk melanoma using interferon-alpha and interleukin-2: preclinical and clinical aspects. In: R Klapdor, ed. Tumor-associated antigens, oncogens, receptors, cytokines at the beginning of the nineties. München: W. Zuckschwerdt Verlag, 1992:664-7.
10. Steis RG, Smith Jd, Urba WJ, et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988;318:1409-13.
11. von Wussow P, Hartmann F, Freund M, Poliwoda H, Deicher H. Leucocyte-derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b [Letter], Lancet 1988;1:882-3.
12. Spiegel RJ. The alpha interferons: clinical overview. Semin Oncol 1987;14:1-12.
13. Bendtzen K, Svenson M, Jonsson V, Hippe E. Autoantibodies to cytokines-friends or foes? Immunol Today 1990;11:167-9.
14. Bocci V. What is the function of autoantibodies to cytokines? [Letter; comment], Immunol Today 1990;11:230-1.
15. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wächter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 1988;9:150-5.
16. 2-Microglobulin. Scand J Clin Lab Invest Suppl 1980;154:13-25.
17. Robb RJ, Kutny RM. Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol 1987;139:855-62.
18. Dummer R, Muller W, Nestle F, et al. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer 1991;67:2300.
19. von Wussow P, Jakschies D, Hochkeppel HK, Fibich C, Penner L, Deicher H. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 1990; 20:2015-9.
20. Becker JC, Winkler B, Klingert S, Brocker EB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 1994;73:1621-4.
21. Weijl NI, Vand HD, Brand A, et al. Hypothyroidism during im-munotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993; 11:1376-83.
22. Cascinelli N, Bufalino R, Morabito A, Mackie R. Results of adjuvant interferon study in WHO melanoma programme [Letter], Lancet 1994;343:913.